EUCTR2021-005790-60-ES进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With Or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •A subject must meet all of the following inclusion criteria to be eligible for enrollment in this study:
- •1. Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma. Subjects with pancreatic acinar cell carcinoma may also be included.
- •2. Is previously untreated for metastatic pancreatic ductal adenocarcinoma; metastatic disease must have been diagnosed within the past 3 months; and subject is expected to receive standard treatment with gemcitabine and nab-paclitaxel. Subjects who have had planned or prior surgery, such as a Whipple procedure, with or without neo-adjuvant/adjuvant chemotherapy may be included.
- •3. Life expectancy =3 months.
- •4. Measurable disease on CT or MRI scan by RECIST v 1.1 criteria.
- •5. ECOG Performance Status 0-1.
- •6. Adult, age = 18 years, male or female.
- •7. Females of child-bearing potential must have a negative serum pregnancy test within 14 days prior to start of study treatment and must use an adequate method of contraception during the study. All sexually active males must also use an adequate method of contraception during the study. Female subjects are considered to be of childbearing potential unless they are postmenopausal (at least 12 months of consecutive amenorrhea, without other known or suspected cause) and over 55 years old or have been sterilized surgically (i.e., bilateral tubal ligation, hysterectomy, or bilateral oophorectomy, all with surgery at least one month before dosing).
- •8. Adequate bone marrow, hepatic, renal, and coagulation function as defined by the following:
- •a. Absolute neutrophil count =1.5 x 109/L
- •b. Hemoglobin =9.0 g/dL (90 g/L)
- •c. Platelets =100 x 109/L
- •d. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5 x upper limit of normal (ULN) (if no hepatic metastases). If hepatic tumor involvement, AST and ALT =5 x ULN.
- •e. Bilirubin =1.5 x ULN
- •f. Calculated creatinine clearance >50 mL/min using the Cockcroft and Gault equation
- •9. QTc interval = 470 msec at Baseline.
- •10. Willing and able to provide written informed consent: voluntary agreement to participate in the study following disclosure of risks and procedures required.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •Subjects are excluded from this study if any of the following conditions are met:
- •1. Subjects known to be BRCA positive.
- •2. Subjects taking metformin. Diabetic subjects on treatment with metformin, or any other derivative thereof, must discontinue it while on study (other diabetic medications are allowed).
- •3. History of retinopathy or macular degeneration.
- •4. Evidence of severe or uncontrolled systemic disease or any concurrent condition that, in the opinion of the Investigator or Medical Monitor, makes it undesirable for the subject to participate in the study or that would jeopardize compliance with the protocol. Subjects with pre-existing well-controlled diabetes are not excluded.
- •5. Medical or psychiatric conditions that compromise the subject’s ability to give informed consent or to complete the protocol or a history of non-compliance.
- •6. Presence of islet-cell or pancreatic neuroendocrine tumor or mixed adenocarcinoma-neuroendocrine carcinoma.
- •7. Symptomatic CNS malignancy or metastasis. Screening of asymptomatic subjects without history of CNS metastases is not required.
- •8. Serum albumin <30 g/L (3.0 g/dL).
- •9. Occurrence of deep vein thrombosis (DVT) or portal vein occlusion, pulmonary embolism (PE), or other thromboembolic event during screening.
- •10. Presence of known active bacterial, fungal, or viral infection requiring systemic therapy.
- •11. Known active infection with human immunodeficiency virus (HIV), hepatitis B or C.
- •12. Presence of interstitial lung disease, pulmonary fibrosis, or pulmonary hypersensitivity reaction.
- •13. Myocardial infarction within the last 12 months, severe/unstable angina, symptomatic congestive heart failure New York Heart Association (NYHA) class III or IV.
- •14. Pregnant or lactating.
- •15. Major surgery within 4 weeks of the start of study treatment, without complete recovery.
- •16. Known hypersensitivity to any component of study treatments.
- •17. Participation in any other clinical investigation within 4 weeks of receiving the first dose of study drug.
- •18. Any history of hydroxychloroquine use (Plaquenil® and other brand names).
研究者
相似试验
进行中（未招募）
1 期
Assessment of efficacy and safety in patients with non-cancer-related pain and opioid-induced constipation.Opioid-induced constipation (OIC)EUCTR2011-001987-24-SKAstraZeneca AB630
进行中（未招募）
1 期
Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosismild to moderate Idiopathic Pulmonary FibrosisMedDRA version: 20.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2017-003158-18-ESBiogen Idec Research Limited290
进行中（未招募）
1 期
A Controlled Study with an active treatment and a Placebo to Assess the Efficacy and Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha-1 Antitrypsin DeficiencyPulmonary Emphysema due to Alpha-1-Antitrypsin DeficiencyMedDRA version: 20.0Level: LLTClassification code 10014563Term: Emphysema pulmonarySystem Organ Class: 100000004855EUCTR2013-001870-38-SEGrifols Therapeutics Inc.339
进行中（未招募）
1 期
A study to assess the efficacy and safety of nemolizumab (CD14152) in subjects with prurigo nodularis (PN)MedDRA version: 20.0Level: LLTClassification code 10037084Term: Prurigo nodularisSystem Organ Class: 100000004858Prurigo NodularisEUCTR2019-004789-17-FRGalderma S.A.240
招募中
3 期
Chronic Migraine in Patients 12 to 17 Years of AgeCTRI/2021/07/034818Eli Lilly and Company India Pvt Ltd